ArticleCureus2026
Myo-Inositol for Cutaneous Manifestations of Polycystic Ovary Syndrome: An International Delphi Consensus Recommendation for Dermatology Practice.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeAcne and hirsutism are among the most distressing features of polycystic ovary syndrome (PCOS), yet current guidelines largely emphasize metabolic and reproductive aspects, offering limited guidance for dermatologic management. Myo-inositol (MI), an insulin-sensitizing agent with endocrine benefits, has emerged as a promising nonhormonal option; however, its role in managing cutaneous symptoms remains unclear. The purpose of this study was to develop expert consensus on the use of MI alone and in combination with folic acid and vitamin D₃ for PCOS-related dermatologic manifestations.
methodsEleven statements were generated through a rigorous literature review and subsequently evaluated by 133 experts through a two-round online Delphi process. Consensus was defined as ≥70% agreement; statements with 50% to <70% agreement were revised and reassessed.
resultsConsensus endorsed MI as an effective and well-tolerated intervention for acne and hirsutism. Continuous MI supplementation at 4 g/day for ≥6 months was recommended. MI + folic acid + vitamin D₃ and MI + D-chiro-inositol were favored for metabolic dysfunction and hyperandrogenism.
conclusionMI-based therapy, particularly early initiation and strategic combinations, should be integrated into multimodal management of PCOS-related cutaneous manifestations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.